跳至主要内容
临床试验/JPRN-UMIN000030453
JPRN-UMIN000030453已完成未知

Efficacy of cyclosporine therapy in the treatment of non-severe aplastic anemia - Aplastic anemia 01 study in West Japan Hematology Study Group (W-JHS AA01 study)

Cooperative study between the West Japan Hematology Study Group and Clinical Research Support Center Kyushu0 个研究点目标入组 34 人开始时间: 2017年12月18日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
34

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
16years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Disease duration >=5 years. Patients whose disease onset is unclear are not excluded. 2) Severe (stage 3 or 4) or moderately severe (stage 3) aplastic anemia that is defined by the severity criteria by the Ministry of Health, Welfare, and Labor of Japan. 3) Patients with chromosomal abnormalities related to MDS that were defined by WHO 2008 diagnostic criteria. 4) Patients showing dysplastic signs defined as category A morphological abnormalities (1. hypo-segmented mature neutrophils (pseudo-Pelger nuclear abnormality), 2. degranulation of neutrophils, 3. micromegakaryocytes, 4. ringed sideroblasts) in "Atlas on diagnosis accuracy division and morphological diagnosis based on morphologic dysplasia of refractory anemia (myelodysplastic syndromes) ". 5) Congenital aplastic anemia including Fanconi anemia. 6) Patients who developed a cancer or received chemotherapy or radiotherapy within 5 years of entry. 7) Patients with uncontrollable infections. 8) Patients with severe impairment of the liver, heart or kidney (eGFR < 45 mL/min/1.73m2). 9) Patients who were judged to be ineligible for the study participation by investigators.

研究者

发起方
Cooperative study between the West Japan Hematology Study Group and Clinical Research Support Center Kyushu

相似试验

Efficacy of cyclosporine therapy in the treatment of... | 临床试验